Brandon Jonseck completed this course through Stanford University Medical School on 11/16/2020. Overview Internet Enduring Material sponsored by the Stanford University School of Medicine. Presented by the Department of Medicine at the Stanford University School of Medicine. This presentation discusses: Monoclonal Antibodies for the Prevention and Treatment of COVID-19. Topics include: Clinical trials and Phase 2 studies. the use of antibody therapy to treat viral infections, how they have been used for a long time, including for the treatment of influenza and SARS 1 and 2. Discussed advantages of mAbs compared with other drugs. Discussed antibody protection develops in nearly all patients with symptomatic COVID-19. Pre-clinical data have identified highly potent neutralizing mAbs and several synergistic mAb combinations. Nearly all mAbs target the RBD and most target ACE2-binding residues. mAbs that cross-neutralize SARS-CoV may protect against other SARS-related C0Vs but are generally less potent against SARS-CoV-2. Most mAbs require minimal affinity maturation explaining why they develop so often, albeit at relatively low levels, among infected persons and in those receiving vaccines. Potent neutralizing mAbs have been consistently protective in animal model challenge studies. Also discussed 3 mAbs that are in phase III trials. Nine additional mAbs are in phase 1 trials and ten more will soon begin phase 1 trials. Credits AMA PRA Category 1 Credits™ (0.50 hours), Non-Physician Participation Credit (0.50 hours) Target Audience Specialties - All Specialties Objectives At the conclusion of this activity, participants should be able to: Analyze pre-clinical and phase 2 study data to determine the effectiveness of monoclonal antibodies for the prevention and treatment of SARS-C0V-2 infections. Accreditation The Stanford University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation The Stanford University School of Medicine designates this Enduring Material for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Additional Information Accessibility Statement Stanford University School of Medicine is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.

1. Stanford Center for Continuing Medical Education | cme.stanford.edu | Email: StanfordCME@stanford.edu
Event ID 39072
Stanford University School of Medicine certifies that
Brandon L Jonseck, MBA
has participated for 0.50 hours in the Enduring Material titled
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
on 11/16/2020
This Activity was designated for 0.50 AMA PRA Category 1 Credit(s)™
Accreditation
The Stanford University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education
(ACCME) to provide continuing medical education for physicians.
Daryl Oakes, MD
Associate Dean for Continuing Medical Education